| A Statistical Framework for Assessing the Relationship between Biomarkers and Clinical Endpoints in Alzheimer’s Disease T Chen, RM Hutchison, C Rubel, J Murphy, J Xie, P Montenigro, W Cheng, ... The Journal of Prevention of Alzheimer's Disease, 1-13, 2024 | | 2024 |
| Cinpanemab in early Parkinson disease: evaluation of biomarker results from the phase 2 SPARK clinical trial RM Hutchison, K Fraser, M Yang, T Fox, E Hirschhorn, E Njingti, D Scott, ... Neurology 102 (5), e209137, 2024 | 5 | 2024 |
| Quantification of Cinpanemab (BIIB054) Binding to α-Synuclein in Cerebrospinal Fluid of Phase 1 Single Ascending Dose Samples YT Liu, M Yang, K Fraser, D Graham, PH Weinreb, A Weihofen, WD Hirst, ... Journal of Pharmacology and Experimental Therapeutics, 2024 | | 2024 |
| Cinpanemab in Early Parkinson Disease RM Hutchison, K Fraser, M Yang, T Fox, E Hirschhorn, E Njingti, D Scott, ... | | 2024 |
| Performance of optimized prototype LUMIPULSE G immunoassays for plasma pTau181 and pTau217 C Lambrechts, M Van Loo, J Vanbrabant, F Dekeyser, S Bayoumy, ... Alzheimer's & Dementia 19, e082944, 2023 | 1 | 2023 |
| Performance of plasma pTau181 and pTau217 measured with fully automated LUMIPULSE G prototype immunoassays J Vanbrabant, S De Meyer, M Van Loo, C Lambrechts, F Accou, ... Alzheimer's & Dementia 19, e079533, 2023 | | 2023 |
| Methods of detecting ube3a protein KB Fraser, OS Mabrouk, DL Graham US Patent App. 17/921,165, 2023 | | 2023 |
| LRRK2 inhibition by BIIB122 in healthy participants and patients with Parkinson's disease D Jennings, S Huntwork‐Rodriguez, MFJM Vissers, VM Daryani, D Diaz, ... Movement Disorders 38 (3), 386-398, 2023 | 31 | 2023 |
| Concordance of CSF biomarkers with amyloid PET at baseline in EMERGE/ENGAGE, phase 3 studies of aducanumab in patients with early Alzheimer’s disease CE Rubel, L Nisenbaum, T Chen, G Dent, K Fraser, D Graham, K Harrison, ... Alzheimer's & Dementia 18, e069382, 2022 | | 2022 |
| LRRK2 Inhibition by BIIB122: Trial designs for two efficacy and safety studies in Parkinson's disease patients with and without LRRK2 mutations (Lighthouse and Luma) J Shirvan, D Jennings, P Wang, R Maciuca, S Sahu, F Sedarati, A Kay, ... MOVEMENT DISORDERS 37, S353-S353, 2022 | | 2022 |
| Trial of cinpanemab in early Parkinson’s disease AE Lang, AD Siderowf, EA Macklin, W Poewe, DJ Brooks, HH Fernandez, ... New England Journal of Medicine 387 (5), 408-420, 2022 | 194 | 2022 |
| G2019S-LRRK2 Expression Augments a-Synuclein Sequestration into Inclusions in Neurons (vol 36, pg 7415, 2016) LA Volpicelli-Daley, H Abdelmotilib, ZLL Stoyka, JPL Daher, ... JOURNAL OF NEUROSCIENCE 42 (4), 718-718, 2022 | | 2022 |
| Glucocerebrosidase activity is not associated with Parkinson's disease risk or severity N Omer, N Giladi, T Gurevich, A Bar‐Shira, M Gana‐Weisz, T Glinka, ... Movement Disorders 37 (1), 190-195, 2022 | 31 | 2022 |
| alpha-Synuclein fibril-induced inclusion spread in rats and mice correlates with dopaminergic Neurodegeneration (vol 105, 84, 98, 2017) H Abdelmotilib, T Maltbie, V Delic, Z Liu, X Hu, KB Fraser, MS Moehle, ... NEUROBIOLOGY OF DISEASE 159, 2021 | | 2021 |
| Corrigendum to" α-Synuclein fibril-induced inclusion spread in rats and mice correlates with dopaminergic Neurodegeneration"[Neurobiol. Dis., Volume 105 (2017) Article 84, 98] H Abdelmotilib, T Maltbie, V Delic, Z Liu, X Hu, KB Fraser, MS Moehle, ... Neurobiology of disease 159, 105506, 2021 | 2 | 2021 |
| Glucocerebrosidase activity does not predict Parkinson's Disease risk or severity N Omer, N Giladi, T Gurevich, A Bar-Shira, M Gana-Weisz, T Glinka, ... MOVEMENT DISORDERS 36, S318-S318, 2021 | | 2021 |
| Cinpanemab in early Parkinson's disease: phase 2 SPARK study results A Lang, A Siderowf, E Macklin, W Poewe, D Brooks, H Fernandez, ... Movement Disorders 36 (S1), S180-S181, 2021 | 3 | 2021 |
| Cinpanemab in Parkinson's Disease: Imaging and Fluid Biomarker Results from the Phase 2 SPARK Study RM Hutchison, K Fraser, M Yang, B Hirschhorn, J Xiao, D Scott, B Bedell, ... MOVEMENT DISORDERS 36, S177-S177, 2021 | 1 | 2021 |
| Physical and molecular landscapes of mouse glioma extracellular vesicles define heterogeneity A Gyuris, J Navarrete-Perea, A Jo, S Cristea, S Zhou, K Fraser, Z Wei, ... Cell reports 27 (13), 3972-3987. e6, 2019 | 58 | 2019 |
| Characterization of single microvesicles in plasma from glioblastoma patients K Fraser, A Jo, J Giedt, C Vinegoni, KS Yang, P Peruzzi, EA Chiocca, ... Neuro-oncology 21 (5), 606-615, 2019 | 96 | 2019 |
